AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 4
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV group
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV group
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV patients
Number of subjects: 98
Study 16527165 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV patients
Number of subjects: 98
Study 12656541 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 44
Study 12656541 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 44
Study 10942095 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 311
Study 10942095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Aminoglutethimide + Hydrocortisone (TAM+AG+H)
Number of subjects: 311
Study 10942095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Fluoxymesterone (TAM+FLU)
Number of subjects: 311
Study 9014599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 89
Study 9014599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 1488420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 96
Study 1488420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipobroman
Number of subjects: 96
Study 2938923 — intervention group
Group type: EXPERIMENTAL
Intervention: Floxuridine infusions into the hepatic artery using a totally implantable pump system (Infusaid, model 400)
Number of subjects: 22
Study 2938923 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 22
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.6 g/kg
Number of subjects: 96
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.4 g/kg
Number of subjects: 96
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol 0.2 g/kg
Number of subjects: 96
Study 31735618 — intervention group
Group type: COMPARATOR
Intervention: Flibanserin 100 mg only
Number of subjects: 96
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg with ethanol (0.2-0.6 g/kg)
Number of subjects: 96
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol (0.4 g/kg and 0.6 g/kg)
Number of subjects: 96
Study 31735618 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg + ethanol
Number of subjects: 96
Study 30253968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 80
Study 30253968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27427876 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based ART
Number of subjects: 219
Study 27427876 — intervention group
Group type: COMPARATOR
Intervention: LPV/r-based ART
Number of subjects: 219
Study 24939642 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing consultation (at least once a month) by a qualified, experienced, specialist nurse in pediatric rheumatology
Number of subjects: 56
Study 24939642 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study 22730760 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-strut stent (strut thickness of 50 microm)
Number of subjects: 651
Study 22730760 — intervention group
Group type: COMPARATOR
Intervention: Thick-strut stent (strut thickness of 140 microm)
Number of subjects: 651
Study 22730760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 1-year rate of death and myocardial infarction
Number of subjects: 651
Study 20337610 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 16
Study 20337610 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 16
Study 19042327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use intervention
Number of subjects: 0
Study 19042327 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16002827 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 0
Study 16002827 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured approaches (meal replacements and food provision)
Number of subjects: 0
Study 12443521 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop smoking and keep walking regime (intervention group)
Number of subjects: 882
Study 12443521 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 882
Study 10711744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 33
Study 10711744 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 33
Study 7568610 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobson's muscle relaxation with encouragement of positive self-esteem
Number of subjects: 22
Study 7568610 — intervention group
Group type: COMPARATOR
Intervention: Control group of 30 students
Number of subjects: 22
Study 1709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chomelanum (preparation A)
Number of subjects: 85
Study 1709335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasonil (preparation B)
Number of subjects: 85
Study 1709335 — intervention group
Group type: COMPARATOR
Intervention: Ointment base of Chomelanum (preparation C)
Number of subjects: 85
Study 6791487 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily
Number of subjects: 28
Study 6791487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31014090 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE-PCI trial patients
Number of subjects: 496
Study 31014090 — intervention group
Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 496
Study 31014090 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including SAFE-PCI and registry patients)
Number of subjects: 496
Study 29171105 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-support programme
Number of subjects: 124
Study 29171105 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 124
Study 27148551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-scoring Score 6 (S6) spermatozoa
Number of subjects: 10
Study 27148551 — intervention group
Group type: COMPARATOR
Intervention: Low-scoring Score 0 (S0) spermatozoa
Number of subjects: 10
Study 25064573 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually Tailored Exercise
Number of subjects: 500
Study 25064573 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Exercise Adherence
Number of subjects: 500
Study 25064573 — intervention group
Group type: COMPARATOR
Intervention: Usual Physiotherapy Care
Number of subjects: 500
Study 22258291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane
Number of subjects: 20
Study 22258291 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol
Number of subjects: 20
Study 20708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 1015
Study 20708349 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 1015
Study 20708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing BZD use
Number of subjects: 1015
Study 20708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular prescription of BZD
Number of subjects: 1015
Study 20708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BZD use
Number of subjects: 1015
Study 18396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (six 1-hour sessions during pregnancy)
Number of subjects: 74
Study 18396254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga program)
Number of subjects: 74
Study 18396254 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 74
Study 15669014 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 home visits by a project nurse or a medical doctor during the first 2 years after discharge
Number of subjects: 249
Study 15669014 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 249
Study 12814272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment (ST) plus Motivational Interviewing
Number of subjects: 120
Study 10915531 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioral skills course and 12-week semistructured exercise course followed by a 3-month problem-solving support intervention
Number of subjects: 64
Study 10915531 — intervention group
Group type: COMPARATOR
Intervention: 12-week semistructured course including facility orientation and three meetings with a personal trainer
Number of subjects: 64
Study 8895642 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Universities osteoarthritis index
Number of subjects: 71
Study 8895642 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Society clinical rating scale
Number of subjects: 71
Study 8895642 — intervention group
Group type: COMPARATOR
Intervention: Short Form‐36
Number of subjects: 71
Study 8895642 — intervention group
Group type: COMPARATOR
Intervention: Time trade off (utility method of measurement)
Number of subjects: 71
Study 1804647 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 50
Study 1804647 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg
Number of subjects: 50
Study 1804647 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine-pseudoephedrine combination
Number of subjects: 50
Study 1804647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6391829 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg meptazinol 4-times daily
Number of subjects: 32
Study 6391829 — intervention group
Group type: COMPARATOR
Intervention: 65 mg dextropropoxyphene plus 650 mg paracetamol 4-times daily
Number of subjects: 32
Study 31738669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/40% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 31738669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/60% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 31738669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown-concentric load (UL) with 100/80% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 31738669 — intervention group
Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/40% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 31738669 — intervention group
Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/60% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 31738669 — intervention group
Group type: COMPARATOR
Intervention: Known-concentric load (KL) with 100/80% of 1RM eccentric/concentric loading
Number of subjects: 17
Study 30901744 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt use frequency
Number of subjects: 377
Study 30901744 — intervention group
Group type: COMPARATOR
Intervention: Joint use frequency
Number of subjects: 377
Study 27974394 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS (10 Hz) applied to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 17
Study 27974394 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 17
Study 27974394 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-rTMS (10 Hz)
Number of subjects: 17
Study 27974394 — intervention group
Group type: COMPARATOR
Intervention: Baseline (patients with MS compared with healthy controls)
Number of subjects: 17
Study 26085822 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 supplementation (5 ml seal oil, 375 mg EPA, 230 mg DPA, 510 mg DHA)
Number of subjects: 30
Study 26085822 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 supplementation
Number of subjects: 30
Study 26085822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml olive oil)
Number of subjects: 30
Study 25796858 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 92
Study 25796858 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD combined with CAC
Number of subjects: 92
Study 25796858 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC in acute phase
Number of subjects: 92
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) enjoyment
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' support for PA
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends' support for PA
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived environmental opportunities for PA
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal stage
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy related to barriers to PA
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support for PA
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social inclusion
Number of subjects: 885
Study 22577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) behavior
Number of subjects: 885
Study 19054706 — intervention group
Group type: EXPERIMENTAL
Intervention: General flexibility assessment using Beighton score (BS)
Number of subjects: 38
Study 19054706 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal force exertion on a six‐component load cell with different thumb support techniques (T1, T2, T3)
Number of subjects: 38
Study 17882582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-radiation neck dissection (pre-RT ND)
Number of subjects: 14
Study 17882582 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional organ preservation treatment)
Number of subjects: 14
Study 14997188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy with radiotherapy
Number of subjects: 0
Study 14997188 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 10975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week dual therapy (lansoprazole 30 mg plus amoxycillin 1 g bid for two weeks)
Number of subjects: 165
Study 10975783 — intervention group
Group type: COMPARATOR
Intervention: One-week triple therapy (lansoprazole 30 mg plus amoxycillin 1 g plus tinidazole 500 mg bid for one week plus lansoprazole qd for an additional week)
Number of subjects: 165
Study 10975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori cured patients
Number of subjects: 165
Study 10975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori not cured patients
Number of subjects: 165
Study 10975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (after one year follow-up)
Number of subjects: 165
Study 10975783 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (after one year follow-up)
Number of subjects: 165
Study 9006835 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue goserelin followed by laparoscopic surgery
Number of subjects: 19
Study 9006835 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue goserelin
Number of subjects: 19
Study 1592541 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg oral sustained release theophylline twice a day
Number of subjects: 34
Study 1592541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 4068672 — intervention group
Group type: EXPERIMENTAL
Intervention: PO2 Aerobic Exerciser
Number of subjects: 17
Study 4068672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PO2 Aerobic Exerciser)
Number of subjects: 17
Study 30401001 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 16867
Study 27329968 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU recombinant human FSH s.c. every other day for 12 weeks
Number of subjects: 89
Study 22445423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active model group (n=176) with self-evaluation kit and treatment of metronidazole 500 mg twice daily for 7 days
Number of subjects: 331
Study 22445423 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=155)
Number of subjects: 331
Study 22053609 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study 22053609 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Number of subjects: 40
Study 18207667 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and preoperative or postoperative radiotherapy or chemoradiation
Number of subjects: 554
Study 15805436 — intervention group
Group type: EXPERIMENTAL
Intervention: FBAT communities
Number of subjects: 5
Study 14623548 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (exemestane, anastrozole)
Number of subjects: 0
Study 14623548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination strategies of gonadotrophin agonists and aromatase inhibitors
Number of subjects: 0
Study 14623548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of aromatase inhibitors
Number of subjects: 0
Study 14623548 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 10714753 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (somatotropin, 0.222 mg/kg/week, divided into 3 doses each week)
Number of subjects: 48
Study 10714753 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 48
Study 10714753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8928847 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg in 10 ml saline)
Number of subjects: 23
Study 8928847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml saline)
Number of subjects: 23
Study 1626990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine 50 mg
Number of subjects: 12
Study 1626990 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 12
Study 4058956 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. naloxone (0.04 mg/kg)
Number of subjects: 13
Study 4058956 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study 31677621 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 40
Study 31677621 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 40
Study 30241688 — intervention group
Group type: EXPERIMENTAL
Intervention: SL edaravone 30 mg
Number of subjects: 10
Study 30241688 — intervention group
Group type: COMPARATOR
Intervention: IV edaravone 30 mg infusion
Number of subjects: 10
Study 30241688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SL and IV administration
Number of subjects: 10
Study 27175799 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training in communication skills and use of a patient booklet
Number of subjects: 2886
Study 27175799 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills and patient booklet
Number of subjects: 2886
Study 27175799 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication groups with a booklet
Number of subjects: 2886
Study 27175799 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care test
Number of subjects: 2886
Study 25236883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus multidisciplinary group clinics
Number of subjects: 198
Study 25236883 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 198
Study 22989231 — intervention group
Group type: EXPERIMENTAL
Intervention: UP4FUN intervention
Number of subjects: 372
Study 22989231 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 372
Study 20864664 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and general practitioner systematic follow-up intervention
Number of subjects: 523
Study 19128346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological management
Number of subjects: 0
Study 19128346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management
Number of subjects: 0
Study 19128346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment plans
Number of subjects: 0
Study 18681992 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐HMG
Number of subjects: 986
Study 18681992 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 986
Study 15164501 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term morphine-clopheline epidural analgesia
Number of subjects: 76
Study 15164501 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (intravenous injection of morphine)
Number of subjects: 76
Study 11308435 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised CONSORT statement
Number of subjects: 0
Study 11308435 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8989246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 IU/day for 12 weeks
Number of subjects: 60
Study 8989246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 IU for 4 weeks followed by 1.2 IU/day for 8 weeks
Number of subjects: 60
Study 8989246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 IU for 4 weeks, followed by 1.2 IU/day for 4 weeks and 1.8 IU/day thereafter
Number of subjects: 60
Study 8989246 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 8989246 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy at doses of 0.6 and 1.2 IU/day
Number of subjects: 60
Study 8285749 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective paralysis (pancuronium during mechanical ventilation)
Number of subjects: 193